Navigation Links
FDA Panel Backs New 'Morning After' Pill
Date:6/17/2010

Marketed as ellaOne in Europe, it extends window of emergency contraception, but opponents see it as abortion drug

THURSDAY, June 17 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel voted unanimously on Thursday to recommend approval of a new emergency contraception pill that is effective for a longer period of time than the "morning after" pill known as Plan B.

The new drug, ulipristal acetate or UPA, is marketed under the brand name ellaOne and would be available only by prescription; it would be effective if taken up to five days after unprotected intercourse. Plan B, another emergency contraceptive, is only effective for up to three days after unprotected sex.

Although the FDA does not always follow the recommendations of its advisory panels, it typically does.

UPA, which is already marketed in 22 European countries, is made by French pharmaceutical company HRA Pharma.

The drug works by inhibiting ovulation, explained Dr. Paul Fine, medical director of Planned Parenthood of Houston & Southeast Texas & Louisiana and a professor of obstetrics, gynecology and urology at Baylor College of Medicine in Houston.

Fine was author of a study published earlier this year in The Lancet that found that UPA cut the risk of an unintended pregnancy in half as compared with levonorgestrel (also known as Plan B, which is now available over-the-counter) in women who took it within five days of unprotected sex.

The possibility of the FDA giving a green light to ellaOne has sparked intense debate as to whether the pill simply prevents pregnancy or actually induces an abortion.

"It is not an abortion pill," said Fine. "The reason for this is that if ovulation has already occurred and fertilization has occurred, then the pregnancy is going to happen. That is also true with Plan B."

"All we can hope is that the FDA advisory committee will listen to the science that's presented, and the science is very compelling that this is a very safe and very effective drug for emergency contraception," he added.

But anti-abortion advocates disagree.

According to Dr. Joe DeCook, a spokesman for the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG), at the doses recommended, ulipristal will not suppress ovulation but will, rather, "block the lining of the uterus from receiving progesterone, which makes it dysfunctional. It will not then support life."

"Life starts when the egg is fertilized. You have a complete genetic human being in a progressive growth stage just like you or me, just smaller than us and less developed," he added. "Ulipristal purposely causes the death of a complete human being, albeit very small and very early. We don't believe it is correct to purposely kill an innocent unborn child, no matter how small."

AAPLOG also has objections on safety grounds, the track record of studies conducted on the pill and, especially, the fact that there is a lack of data on the use of minors using the drug.

An FDA report issued earlier this week found UPA to be safe with no untoward side effects, reported Agence France-Presse (AFP). The FDA's review found the most common side effects to be nausea, headache, uterine pain, abdominal pain, fatigue and dizziness, AFP said.

Other more serious side effects did not seem to be due to the drug, the FDA stated.

At lower doses, UPA is being tested in late clinical trials as a treatment for uterine fibroids, according to Planned Parenthood.

More information

For more on contraception, visit the U.S. National Library of Medicine.



SOURCES: Paul Fine, M.D., medical director, Planned Parenthood of Houston & Southeast Texas & Louisiana, and professor, obstetrics, gynecology and urology, Baylor College of Medicine, Houston; Joseph DeCook, M.D., spokesman, American Association of Pro-Life Obstetricians and Gynecologists; Agence France-Presse


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Panel to Vote on New Morning After Pill
2. U.S. Panel Upholds Ban on Gay Men as Blood Donors
3. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
4. DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It
5. ANY LAB TEST NOW Launches New Infectious Disease Panels - Affordable Panels Test for H1N1, Staph, E. coli and Other Infectious Diseases
6. PSA-TEC to Present State of the Industry Panel Discussion
7. Panel recommends standardizing prescription container labeling
8. HIA-LI 22nd Annual Business Trade Show & Conference to Feature Healthcare Pavilion and Expert Panel Discussing Healthcare Economics and Politics
9. Review Panel Leaves Controversial Lyme Disease Guidelines Unchanged
10. R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting
11. FDA Panel Weighs New Restrictions on Tanning Beds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Backs New 'Morning After' Pill
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: